Clinical and radiographic outcomes of the modified minimally invasive surgical technique with or without platelet rich fibrin for the treatment of intrabony defects : a randomized clinical trial - M-MIST technique with or without PRF for intrabony defects treatment

Start Date28 Aug 2023

Sponsor / Collaborator-

CTRI/2023/06/054222

/ Not yet recruitingNot ApplicableIIT

Evaluation of Morinda citrifolia(NONI) fruit extract powder in combination with I-PRF and I-PRF alone: A Randomized Controlled Trial.

Start Date30 Jun 2023

Sponsor / Collaborator-

CTRI/2023/06/053989

/ Not yet recruitingNot ApplicableIIT

A Comparative evaluation of treatment outcomes of coronal pulpotomy using biodentine alone versus combination of PRF & biodentine in mature permanent mandibular molars diagnosed with irreversible pulpitis: a randomized controlled clinical trial

Start Date20 Jun 2023

Sponsor / Collaborator-

100 Clinical Results associated with Lanreotide Acetate

100 Translational Medicine associated with Lanreotide Acetate

100 Patents (Medical) associated with Lanreotide Acetate

1,952

Literatures (Medical) associated with Lanreotide Acetate

01 Mar 2025·Journal of Hazardous Materials

Leaching behavior and stabilization/solidification characterization of heavy metals from silicomanganese slag

Article

Author: Huang, Xiaoyan ; Yao, Jun ; Zhao, Yuhui ; Yu, Wenjing ; Ni, Wen ; Bu, Yongguang ; Zhang, Siqi

The utilization of silicomanganese slag (SMS) for the partial substitution of cement holds significant importance in handling environmental risks and achieving the harmless and resourceful utilization of industrial solid wastes. Nevertheless, an in-depth analysis of the leaching behaviors of heavy metals and the solidification/stabilization mechanisms in SMS and cementitious materials is still lacking. In this study, we adopted the toxicity characteristic leaching procedure and horizontal vibration method to simulate the natural leaching environment, thereby exploring the leaching risks related to heavy metals in the aforementioned materials. The results indicated that the release and migration of heavy metals were highly reliant on environmental pH values. Among them, Mn predominantly existed in SMS in the form of acid extractable fraction, and its dissolution was mainly governed by rhodochrosite and hausmannite. Fortunately, cementitious materials fabricated from SMS can conspicuously prevent the leaching of heavy metals such as Mn, Cr, Ni and As. The mechanism analysis disclosed that heavy metals can be effectively immobilized by silicon-aluminum structures through physical encapsulation, ion exchange, and lattice confinement during slurry hydration, and gradually shift from an unstable state to a more stable one. These findings offer profound insights for the sustainable application of SMS in the environment.

01 Feb 2025·Pituitary

IGF-I levels during standard Lanreotide dose predicts biochemical outcome of high-frequency regimen in acromegaly

Article

Author: Chiloiro, Sabrina ; Giambò, Penelope ; Gaudino, Simona ; De Marinis, Laura ; Giampietro, Antonella ; Pontecorvi, Alfredo ; Olivi, Alessandro ; Rindi, Guido ; Mattogno, Pier Paolo ; Bianchi, Antonio ; Lauretti, Liverana ; Gessi, Marco ; Costanza, Flavia ; Giustina, Andrea ; Calandrelli, Rosalinda ; Doglietto, Francesco

INTRODUCTIONFirst-generation somatostatin receptor ligands (fg-SRLs) are the cornerstone of acromegaly treatment. Additional benefits were shown using high dose (HD) or high frequency (HF), relatively short-term regimens. Although several predictors of response to standard dose (SD)-fg-SRLs were reported, outcome biomarkers for HF administration are not yet available. Here, we aimed to identify predictors of response to long-term HF-fg-SRLs.PATIENTS AND METHODSA retrospective study was performed on 102 patients, treated with Lanreotide. Patients not controlled at 12 months of SD-Lanreotide (120 mg/28 days) were switched to HF-Lanreotide (120 mg/21 days) for additional 12 months.RESULTSTwenty-eight patients were controlled at 6 months of SD-Lanreotide (27.4%); 35 patients were controlled at 12 months of treatment (34.3%). Out of 67 patients treated with HF- Lanreotide, 18 (26.9%) were controlled at 6 months of treatment and remained controlled until 12 months. Both during SD and HF-Lanreotide administrations, IGF-I levels were reduced during the first six months of treatment (p < 0.001), without further significant reduction between 6 and 12 months of therapy. Response at 12 months of SD-Lanreotide was predicted by IGF-I reached at six months of SD-Lanreotide (p = 0.024). Response at 12 months of HF-Lanreotide treatment was predicted by IGF-I levels reached at six months of SD-Lanreotide treatment (p = 0.04) and six months of HF-Lanreotide treatment (p = 0.01).CONCLUSIONOur results demonstrated that initial IGF-I levels during SD-Lanreotide predicted the biochemical outcome after 12 months of HF-Lanreotide. Patients in whom HF-Lanreotide did not normalize IGF-I after 6 months of treatment remained uncontrolled 12 months after starting this regimen.

10 Jan 2025·Endocrine Reviews

Structure and Function of Somatostatin and Its Receptors in Endocrinology

Review

Author: Xue, Li ; Wu, Zhe Bao ; Zhang, Bo

AbstractSomatostatin analogs, such as octreotide, lanreotide, and pasireotide, which function as somatostatin receptor ligands (SRLs), are the main drugs used for the treatment of acromegaly. These ligands are also used as important molecules for radiation therapy and imaging of neuroendocrine tumors. Somatostatin receptors (SSTRs) are canonical G protein-coupled proteins that play a role in metabolism, growth, and pathological conditions such as hormone disorders, neurological diseases, and cancers. Cryogenic electron microscopy combined with the protein structure prediction platform AlphaFold has been used to determine the 3-dimensional structures of many proteins. Recently, several groups published a series of papers illustrating the 3-dimensional structure of SSTR2, including that of the inactive/activated SSTR2-G protein complex bound to different ligands. The results revealed the residues that contribute to the ligand binding pocket and demonstrated that Trp8-Lys9 (the W-K motif) in somatostatin analogs is the key motif in stabilizing the bottom part of the binding pocket. In this review, we discuss the recent findings related to the structural analysis of SSTRs and SRLs, the relationships between the structural data and clinical findings, and the future development of novel structure-based therapies.

News (Medical) associated with Lanreotide Acetate

23 Oct 2024

·www.globenewswire.com

Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance

PARIS, FRANCE, 23 October 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its performance for the year to date and the third quarter of 2024. YTD 2024 YTD 2023 % change Q3 2024 Q3 2023 % change €m €m Actual CER1 €m €m Actual CER1 Oncology 1 829,8 1 744,1 4,9% 5,8% 604,0 574,5 5,1% 5,6% Neuroscience 536,4 489,0 9,7% 11,8% 181,9 164,8 10,4% 10,1% Rare Disease 129,7 76,0 70,7% 71,3% 50,8 33,2 53,1% 54,4% Total Sales 2 495,9 2 309,1 8,1% 9,2% 836,6 772,4 8,3% 8,6% Highlights Total-sales growth in the year to date of 9.2% at CER1, or 8.1% as reported, with notable performances from Dysport® (abobotulinumtoxinA), Cabometyx® (cabozantinib) and Bylvay® (odevixibat), with robust Somatuline® (lanreotide) sales, as well as the increasing contribution from the launches of Iqirvo® (elafibranor) in 2L PBC2 and Onivyde® (irinotecan) in 1L mPDAC3 Regulatory approvals in the E.U. of Iqirvo and Kayfanda® (odevixibat)Increased 2024 financial guidance: total-sales growth greater than 8.0% at CER1 (prior guidance: greater than 7.0% at CER1); core operating margin greater than 31.0% of total sales (prior guidance: greater than 30.0%) “Since the launch of our strategy in 2020, we have enjoyed uninterrupted growth. This quarter was no exception and was accompanied by further progress in the pipeline”, commented David Loew, Chief Executive Officer. “We have also continued to launch across several indications and lines of therapy, including the recent rollouts of Iqirvo and Onivyde, which are progressing well. Supported by the performance so far this year, we are further increasing our 2024 sales and margin guidance.” “We have built a track record of delivery, grounded in a strong foundation of external innovation, commercial excellence and our ongoing mission to offer more choices for patients.” Full-year 2024 guidance Based on the strong performance in the third quarter, Ipsen has further increased its financial guidance for 2024: Total-sales growth greater than 8.0%, at constant currency (prior guidance of greater than 7.0%). Based on the average level of exchange rates in September 2024, an adverse impact on total sales of around 1.5% from currencies is expectedCore operating margin greater than 31.0% of total sales (prior guidance of greater than 30.0%) Pipeline update In September 2024, the European Commission conditionally approved Iqirvo 80mg tablets for the treatment of PBC in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as a monotherapy in patients unable to tolerate UDCA. Iqirvo was approved in the same setting by the U.S. FDA in June 2024. In September 2024, the European Commission also approved Kayfanda as a treatment for pruritus in children from as young as six months of age who have Alagille syndrome (ALGS). Odevixibat, under the brand name Bylvay, is already marketed in the E.U. for the treatment of progressive familial intrahepatic cholestasis (PFIC), and in the U.S. and E.U. for PFIC, and in the U.S. for ALGS. In the same month, final results from the CABINET Phase III trial were presented at the 2024 European Society for Medical Oncology Congress and were published in the New England Journal of Medicine, reinforcing the efficacy benefits of Cabometyx in advanced neuroendocrine tumors. It was announced at that time that Ipsen had submitted an extension of indication Marketing Authorization to the European Medicines Agency. Business development In August 2024, Ipsen entered into an agreement to sell its rare pediatric disease Priority Review Voucher. As part of the agreement, Ipsen received a cash payment of $158m in the third quarter. In October 2024, Eton Pharmaceuticals entered into an agreement with Ipsen to acquire Increlex® (mecasermin injection). The transaction is expected to close before the end of 2024. Arbitration proceedings with Galderma As of 30 September 2024, two arbitration proceedings initiated by Galderma against Ipsen at the International Chamber of Commerce (ICC) were ongoing. The first dispute, initiated by Galderma in 2021, pertains to the territorial scope of the commercial partnership related to Azzalure® (abobotulinumtoxinA) and Dysport under an agreement signed in 2007 in the E.U., in certain Eastern European countries, and in Central Asia. The Tribunal of the ICC Internal Court of Arbitration issued a final award, in October 2024, dismissing most, if not all, of Galderma's claims in this first arbitration and ordered that Galderma bear the majority of the legal fees and arbitration costs incurred by Ipsen. A second dispute was initiated by Galderma in November 2023, related to the validity of Ipsen’s 2023 termination of a joint R&D collaboration agreement entered into in 2014 under the parties’ respective early-stage neurotoxin programs, including the development of IPN10200. At this stage, Ipsen cannot reasonably predict any potential financial impact from this final remaining arbitration process, for which it intends to fully defend and vindicate its rights. Conference call A conference call and webcast for investors and analysts will begin today at 2pm CET. Participants can access the call and its details by registering here; webcast details can be found here. Calendar Ipsen intends to publish its full-year and fourth-quarter results on 13 February 2025. Notes All financial figures are in € millions (€m). The performance shown in this announcement covers the nine-month period to 30 September 2024 (YTD 2024) and the three-month period to 30 September 2024 (Q3 2024), compared to the nine-month period to 30 September 2023 (YTD 2023) and the three-month period to 30 September 2023 (Q3 2023), respectively. Commentary is based on the performance in YTD 2024, unless stated otherwise. About Ipsen Ipsen is a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fuelled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com. Ipsen contacts Investors Craig Marks +44 (0)7584 349 193 Nicolas Bogler +33 6 52 19 98 92 Media Jennifer Smith-Parker +44 (0) 7843 137 764Anne Liontas +33 7 67 34 72 96 1 At constant exchange rates (CER), which excludes any foreign-exchange impact by recalculating the performance for the relevant period by applying the exchange rates used for the prior period.2 Second-line primary biliary cholangitis.3 First-line metastatic pancreatic ductal adenocarcinoma. Attachment Ipsen - YTD 2024 sales announcement

Drug ApprovalPhase 3Clinical ResultLicense out/in

22 Oct 2024

·www.camurus.com

Camurus provides regulatory update on the US NDA for CAM2029 in acromegaly

Lund, Sweden — 22 October 2024 — Camurus (NASDAQ STO: CAMX) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the new drug application (NDA) for CAM2029 (octreotide) extended-release injection for the treatment of patients with acromegaly. The CRL is attributed to facility-related deficiencies identified during a Current Good Manufacturing Practices (cGMP) inspection of a third-party manufacturer completed in September 2024. FDA has communicated that its determination of responses from the facility as satisfactory is needed for a timely resolution of the CRL and approval of the NDA. The CRL did not state any other concerns, including related to clinical efficacy or safety of CAM2029. “The CRL is disappointing, however, we are confident in the data supporting our NDA and the potential of CAM2029 to address unmet medical needs of patients with acromegaly”, says Fredrik Tiberg, Camurus’ President & CEO. “Camurus is committed to working with the FDA and the third-party manufacturer to bring CAM2029 to patients living with acromegaly as soon as possible.” Labelling discussions with the FDA were held during the final stage of the NDA review and the prescribing information for CAM2029 is well advanced. In parallel with the US NDA process, a Market Authorization Application for CAM2029 for the treatment of acromegaly is under review in the EU. In addition, two development programs for CAM2029 for treatment of gastroenteropancreatic neuroendocrine tumors and polycystic liver disease are progressing. The CRL does not impact on the advancement of these programs. For more information Fredrik Tiberg, President & CEO Tel. +46 (0)46 286 46 92 fredrik.tiberg@camurus.com Fredrik Joabsson, Chief Business Development Officer Tel. +46 (0)70 776 17 37 ir@camurus.com About acromegaly Acromegaly is a rare, slowly progressive disease, typically caused by a tumor of the pituitary gland producing excess growth hormone and stimulating increased insulin growth factor-1 (IGF-1) levels. This results in abnormal growth of bone and tissue, enlarged hands, feet, facial features and inner organs, and symptoms such as fatigue, joint pain, headache, visual field defects, excessive sweating, and paresthesia.1 Inadequate biochemical and symptom control can have detrimental impacts on quality of life and mortality of patients with acromegaly.2,3 The prevalence of acromegaly is estimated to about 60 cases per million.4 About CAM2029 Octreotide SC depot, CAM2029, is an investigational, ready-to-use octreotide for subcutaneous administration under development for the treatment of acromegaly, as well as gastroentero-pancreatic neuroendocrine tumors (GEP-NET), and polycystic liver disease (PLD). CAM2029 is designed for enhanced octreotide exposure and convenient, once-monthly administration with a prefilled pen to facilitate easy self-administration by patients. The CAM2029 clinical program for acromegaly comprises of seven clinical trials, including four Phase 1 studies, one Phase 2 study, and two Phase 3 studies within the ACROINNOVA clinical program. CAM2029 has demonstrated an approximate five-fold higher bioavailability compared to the currently approved, long-acting, intramuscular (IM) octreotide.5 In the Phase 3 ACROINNOVA program, CAM2029 showed superior biochemical control compared to placebo as well as improvements in symptom control, treatment satisfaction, and quality of life compared to SoC at baseline with first-generation somatostatin receptor ligands (SRLs), octreotide and lanreotide. The safety profile of CAM2029 was consistent with SoC with no new findings.6,7 CAM2029 has received orphan drug designation for acromegaly (EU) and for polycystic liver disease (EU and US). About Camurus Camurus is a Swedish, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of dependence, pain, cancer and endocrine diseases, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com. References Colao A., et al. Acromegaly. Nat Rev Dis Primers. 2019;5(1):20. Webb SM, et al. Quality of Life in Acromegaly. Neuroendocrinology. 2016;103(1):106-111. Fleseriu M, et al Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 2022 Nov;10(11):804-826. Crisafulli S., et al. Global epidemiology of acromegaly: a systematic review and meta-analysis. Eur J Endocrinology. 2021; 185:251-63. Prescribing Information SANDOSTATIN® LAR, https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021008Orig1s047Corrected_lbl.pdf Ferone, D., et al. Octreotide subcutaneous depot for acromegaly: A randomized, double-blind, placebo-controlled phase 3 trial, ACROINNOVA 1. J Clin Endocrinol Metab. Published 8 October, 2024. https://doi-org.libproxy1.nus.edu.sg/10.1210/clinem/dgae707 Press release 15 July, 2024: https://www.camurus.com/media/press-releases/2024/camurus-announces-positive-phase-3-results-from-the-acroinnova-2-study-of-octreotide-sc-depot-cam2029-in-acromegaly-patients/ This information is information that Camurus AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the managing director, at 1:00 am CET on 22 October 2024.

Clinical ResultPhase 3Orphan DrugNDAPhase 2

20 Sep 2024

·www.camurus.com

EMA positive opinion for orphan drug designation to Camurus’ octreotide SC depot for the treatment of polycystic liver disease

Lund, Sweden — 20 September 2024 — Camurus (NASDAQ STO: CAMX) today announced that the Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency (EMA) has adopted a positive opinion for orphan drug designation (ODD) to the company’s investigational medicinal product, octreotide subcutaneous (SC) depot (CAM2029), for the treatment of autosomal dominant polycystic liver disease (PLD). The European Commission is now assessing the opinion and is expected to grant the designation within 30 days. PLD is a rare, genetic, and chronic disorder characterized by progressive growth of cysts in the liver, which can cause severe symptoms and result in impaired quality of life for patients. An estimated 37,000 patients in the US and EU are today living with PLD, of which a majority are women.1 “The positive opinion by the EMA underpins the need of a treatment for patients living with polycystic liver disease, for which there today is no approved pharmaceutical treatment in the EU”, says Dr Fredrik Tiberg, President & CEO of Camurus. “CAM2029 is currently being assessed for efficacy and safety in the POSITANO clinical study in patients with symptomatic PLD, with topline results expected in the first half of 2025.” CAM2029 has previously been granted ODD for the treatment of autosomal dominant PLD by the US Food and Drug Administration (FDA)2 and ODD for the treatment of acromegaly in the EU. For more information about EMA’s ODD program, visit: https://www.ema.europa.eu/en/human-regulatory/research-development/orphan-designation-research-development For more information Fredrik Tiberg, President & CEO Tel. +46 (0)46 286 46 92 fredrik.tiberg@camurus.com Fredrik Joabsson, Chief Business Development Officer Tel. +46 (0)70 776 17 37 ir@camurus.com About PLD Polycystic liver disease (PLD) is a rare genetic and chronic disorder characterized by progressive growth of fluid-filled cysts in the liver, which can cause severe symptoms such as abdominal pain and discomfort, shortness of breath (dyspnea), indigestion (dyspepsia), gastro-esophageal reflux, and limited mobility. Rare complications are hepatic cyst hemorrhage and infection or rupture.3-6 Age and gender contribute to disease severity; increasing age is positively associated with both cyst sizes and numbers, and women are highly overrepresented among symptomatic patients.7-9 Most patients with PLD are diagnosed in their 30s after reporting a sudden and accelerated increase of abdominal breadth together with PLD-related symptoms.8 There is currently no approved pharmacological treatment for PLD. Clinical studies indicate that somatostatin receptor ligands, e.g., octreotide, can slow down cyst growth, decrease fluid secretion, and reduce the liver volume.10-12 About octreotide SC depot (CAM2029) CAM2029 is a ready-to-use, long-acting subcutaneous depot of octreotide under development for treatment of three rare disease indications: acromegaly, gastroenteropancreatic neuroendocrine tumors (GEP-NET), and polycystic liver disease (PLD). CAM2029 has been evaluated in a comprehensive clinical program, including five Phase 1 and 2 studies, two Phase 3 studies in acromegaly (ACROINNOVA 1 and 2), an ongoing Phase 3 study in patients with GEP-NET (SORENTO), and an ongoing Phase 2/3 study in patients with PLD (POSITANO). CAM2029 is designed for enhanced octreotide exposure and convenient, once-monthly administration with a prefilled autoinjector pen to facilitate easy self-administration by patients. About the POSITANO study POSITANO is a randomized, double-blind, placebo-controlled Phase 2/3 study evaluating efficacy and safety of CAM2029 in patients with symptomatic PLD. Primary endpoint is change in height-adjusted total liver volume (htTLV) and first secondary endpoint is change in self-reported disease symptoms. For more information, visit www.clinicaltrials.gov (NCT05281328). About Camurus Camurus is a Swedish, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of dependence, pain, cancer and endocrine diseases, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com. References Est. in US and EU4+UK. Globe Life Sciences report 2020; data on file. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=836621 bu-Wasel, B., et al. Pathophysiology, epidemiology, classification and treatment options for polycystic liver diseases. World J Gastroenterol. 2013. 19(35): p. 5775-86. Perugorria, M.J., et al. Polycystic liver diseases: advanced insights into the molecular mechanisms. Nat Rev Gastroenterol Hepatol. 2014. 11(12): p. 750-61. Neijenhuis, M.K., et al. Impact of liver volume on polycystic liver disease-related symptoms and quality of life. United European Gastroenterol J. 2018. 6(1): p. 81-88. Olaizola P., et al. Genetics, pathobiology and therapeutic opportunities of polycystic liver disease. Nat Rev Gastroenterol Hepatol. 2022 May 13. van Keimpema L., et al. Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases. Liver international. 2011;31(1):92-8. van Aerts RMM, et al. Clinical management of polycystic liver disease. J Hepatol. 2018;68(4):827-37.50. van Aerts RMM, et al. Severity in polycystic liver disease is associated with aetiology and female gender: Results of the International PLD Registry. Liver international. 2019;39(3):575-82. Gevers T. J. G., et al. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial. Liver International. 2015 May;35(5):1607-14. Pisani A., et al. Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease. Clin Gastroenterol Hepatol. 2016 Jul;14(7):1022-1030. van Aerts RMM, et al., Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease. Gastroenterology. 2019 Aug;157(2):481-491. This information was submitted for publication at 8:00 am CET on 20 September 2024.

Orphan DrugPhase 1Oligonucleotide

100 Deals associated with Lanreotide Acetate

External Link

KEGG	Wiki	ATC	Drug Bank
D04666	Lanreotide Acetate	H01CB03	DB06791

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pituitary Neoplasms	JP	Teijin Ltd.	15 Jan 2021
Gigantism	JP	Teijin Ltd.	08 Jan 2013
Gastro-Enteropancreatic Neuroendocrine Tumor	AU	Ipsen Pty Ltd.	11 Sep 2003
Carcinoid Tumor	KR	Ipsen Ltd.	08 Aug 2002
Neuroendocrine Tumors	KR	Ipsen Ltd.	08 Aug 2002
Acromegaly	CN	Ipsen Pharma Biotech SAS	14 Mar 2002
Malignant Carcinoid Syndrome	CN	Ipsen Pharma Biotech SAS	14 Mar 2002

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Carcinoma	Phase 2	FR	Ipsen SA	01 Sep 2003
Carcinoma	Phase 2	BE	Ipsen SA	01 Sep 2003
Carcinoma	Phase 2	NL	Ipsen SA	01 Sep 2003
Intestinal Obstruction	Phase 2	BE	Ipsen SA	01 Sep 2003
Intestinal Obstruction	Phase 2	FR	Ipsen SA	01 Sep 2003
Acromegaly	Phase 2	CH	Ipsen SA	01 Sep 2000
Acromegaly	Phase 2	FR	Ipsen SA	01 Sep 2000
Digestive System Fistula	Phase 2	RU	Ipsen SA	01 Apr 2000
Digestive System Fistula	Phase 2	FR	Ipsen SA	01 Apr 2000
Intestinal Obstruction	Phase 1	NL	Ipsen SA	01 Sep 2003

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04852679 (PALACE, CTgov)	Phase 3	Gastro-Enteropancreatic Neuroendocrine Tumor	43	Lanreotide autogel	npaeiwlukl(pvtejzepgf) = zsiaicaees kwzaymypyo (wtqjhahfdq, sndsyivyim - yacfhkgihq) View more	-	01 Oct 2024
ENDO2024	Not Applicable	Acromegaly IGF-1	10	Lanreotide depot	dexccwsygu(vageikphwd) = nnhlavoexx xvxqoexptj (amkvkzpqvc )	-	01 Jun 2024
ENDO2024	Not Applicable	Acromegaly IGF-1	10	Octreotide LAR	dexccwsygu(vageikphwd) = tqejjkfasg xvxqoexptj (amkvkzpqvc )	-	01 Jun 2024
PRESTO 3 (ENDO2023)	Not Applicable	-	94	Lanreotide (Somatuline Autogel syringe)	kxazlvypzw(tiubtawbzx) = sqmhupveli yusgkpefpd (prtcsaqeyc, 77.5 - 92.4)	Positive	05 Oct 2023
NCT02859064 (CTgov)	Phase 2	Carcinoid Tumor \| Gastro-Enteropancreatic Neuroendocrine Tumor	6	Y-90 microspheres+Lanreotide	jekemxiggt(kvojbfsrdv) = kpgwsvbvjm hbxwcbsfiw (dtsziberwh, rpizetopsy - envkteebko) View more	-	27 Jul 2023
NCT01538966 (CTgov)	Not Applicable	Acromegaly	76	Pegvisomant+Octreotide LAR+Lanreotide (High Dose SRL + Weekly Pegvisomant)	ltpyisysze(dvesprrbzk) = yfqulwofef vnpszyvopg (qhyoyxdkys, ldkzsyxaxo - iclbnrqxgx) View more	-	04 Jan 2023
NCT01538966 (CTgov)	Not Applicable	Acromegaly	76	Pegvisomant+Octreotide LAR+Lanreotide (Low Dose SRL + Daily Pegvisomant)	ltpyisysze(dvesprrbzk) = cycsyvlymw vnpszyvopg (qhyoyxdkys, rlbiivfkne - lgbkchjjay) View more	-	04 Jan 2023
PSAT041 (ENDO2022)	Not Applicable	Cushing Syndrome	-	Lanreotide	(onrpfxhqjf) = gerwnypnhf zdofbpxeyj (bypkisofvl ) View more	-	01 Nov 2022
NCT02288377 (REMINET \| Prodige 31 REMINET, CTgov)	Phase 2/3	Neuroendocrine Tumors	53	Placebo (Placebo)	upvkooviow(hbmluxjrzy) = jrvzbkuobj gfuflxgghz (caxzzeuntk, fnvqwsqviu - fwtvzuzcmp) View more	-	04 Oct 2021
NCT02288377 (REMINET \| Prodige 31 REMINET, CTgov)	Phase 2/3	Neuroendocrine Tumors	53	lanreotide (Lanreotide)	upvkooviow(hbmluxjrzy) = pmmjzfytyd gfuflxgghz (caxzzeuntk, wbwwhbhang - ziijcbtujx) View more	-	04 Oct 2021
EUCTR2015-004992-62-DE \| NCT02683941 (SPINET, ESMO 12021 \| ESMO 22021) Manual	Phase 3	Neuroendocrine Tumors SSTR Positive	77	Lanreotide autogel/depot	(umfmawzppw) = ifxrnenind jbetxyeepv (jsbifnlmsr, 11.3–21.9) View more	Positive	21 Sep 2021
	Phase 3	Neuroendocrine Tumors SSTR Positive	77	Lanreotide autogel/depot (OL-LAN)	(vkjtntwkqm) = czvplvbdyo sgqlahieyg (ktgtppejnd ) View more	Positive	21 Sep 2021
NCT03043664 (PLANET, ASCO_GI 12021 \| ASCO_GI 22021) Manual	Phase 1/2	Gastro-Enteropancreatic Neuroendocrine Tumor	22	pembrolizumab+lanreotide	(ztjgghgfeb) = oneqydoyqc ramljqghkw (sfijbmeybi, 1.7 - 8.3) View more	Negative	22 Jan 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Lanreotide Acetate

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation